Zynerba Pharmaceuticals Inc., of Devon, Pa., reported data from the phase II STAR 1 (Synthetic Transdermal Cannabidiol for the Treatment of Epilepsy) trial and ongoing STAR 2 18-month open-label extension study testing ZYN002, a cannabidiol transdermal gel, in patients with focal seizures at the 2017 Annual Meeting of the American Epilepsy Society in Washington.